Dexmethylphenidate Extended Release

@article{Moen2009DexmethylphenidateER,
  title={Dexmethylphenidate Extended Release},
  author={Marit D. Moen and Susan J. Keam},
  journal={CNS Drugs},
  year={2009},
  volume={23},
  pages={1057-1083}
}
SummaryAbstractDexmethylphenidate extended release (XR) [Focalin® XR] is a CNS stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in patients aged ≥6 years. Dexmethylphenidate contains the d-threo- enantiomer of methylphenidate. Dexmethylphenidate XR capsules have a bimodal release profile, which mimics two doses of dexmethylphenidate immediate release (IR) given 4 hours apart, and allows once-daily administration.Once-daily dexmethylphenidate XR was… 

Efficacy and safety of extended-release dexmethylphenidate compared with d,l-methylphenidate and placebo in the treatment of children with attention-deficit/hyperactivity disorder: a 12-hour laboratory classroom study.

d-MPH-ER and d,l-MPh-ER improved ADHD symptoms and were well tolerated and all active treatments provided a significant benefit over placebo at most time points to 12 hours post-dosing.

An update on the pharmacokinetic considerations in the treatment of ADHD with long-acting methylphenidate and amphetamine formulations

Since there are no reliable biomarkers that can predict individualized response to long-acting stimulants, clinicians need to consider their distinctive pharmacokinetic properties, including the pharmacokinetics profile, rate and extent of absorption, variability, dose proportionality, bioequivalence and potential for accumulation.

Analytically Confirmed Intoxication by 4-Fluoromethylphenidate, an Analog of Methylphenidate.

This report represents the first case of an analytically confirmed non-fatal intoxication by 4F-MPH, a halogenated derivative of methylphenidate used for the treatment of attention deficit hyperactivity disorders, which was admitted to the emergency department with neuropsychiatric and cardiologic symptoms that lasted for a week.

Risk of Serious Cardiovascular Problems with Medications for Attention-Deficit Hyperactivity Disorder

The risk for serious cardiovascular adverse events associated with stimulants, atomoxetine or α2-adrenergic agonists prescribed for ADHD is extremely low and the benefits of treating individual patients with ADHD, after an adequate assessment, outweigh the risks.

Analytical characterization and pharmacological evaluation of the new psychoactive substance 4-fluoromethylphenidate (4F-MPH) and differentiation between the (±)-threo and (±)-erythro diastereomers.

The identification and analytical characterization of two powdered 4F-MPH products obtained from an online vendor in 2015 suggest that the psychostimulant properties of (±)-threo-4F- MPs might be more potent in humans than MPH.

Evolution of stimulants to treat ADHD: transdermal methylphenidate

The following comprehensive review describes the evolution of stimulant drug formulations used in the treatment of attention‐deficit/hyperactivity disorder (ADHD). Emphasis is placed on the basic and

Statistical Methods for Evaluating Relational Structures in Multi-Dimensional Phenotypic Data for Neuropsychiatric Disorders

Author(s): Shih, Vivian H | Advisor(s): Sugar, Catherine A | Abstract: While awareness and detection of neuropsychiatric disorders have been on the rise since the mid-twentieth century, current

The nonmedical use of prescription stimulants among dental and dental hygiene students.

The purpose of this study was to determine the nonmedical use of prescription attention deficit disorder (ADD) stimulant medication among dental and dental hygiene students and to help administrators and faculty members become aware of potential problems with the misuse of ADD stimulants.

Overdiagnosis of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents

This systematic scoping review evaluates the multidecade pattern of diagnosis in attention-deficit/hyperactivity disorder in young people using a framework for identifying overdiagnosis for noncancer

Progress on transition metal catalyzed asymmetric hydroesterification, hydrocarboxylation, and hydroamidation reactions of olefins.

Hydrocarboxylation, hydroesterification, and hydroamidation of olefins are fundamental transformations in organic synthesis. Asymmetric processes for these transformations provide an effective and

References

SHOWING 1-10 OF 56 REFERENCES

Dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder.

D-MPH-ER provided sustained improvement in attention, deportment, and academic productivity throughout the 12-hour laboratory day.

Similar bioavailability of dexmethylphenidate extended (bimodal) release, dexmethyl-phenidate immediate release and racemic methylphenidate extended (bimodal) release formulations in man.

A modified release formulation with bimodal release for the pure d-enantiomer (Focalin XR) has been developed to enable a fast onset of action and a sustained activity for once-daily administration and demonstrated a bimmodal concentration-time profile.

Long-Term Effectiveness and Safety of Dexmethylphenidate Extended-Release Capsules in Adult ADHD

Once-daily d-MPH-ER 20 to 40 mg is safe and effective for long-term treatment of adult ADHD.

Efficacy and safety of dexmethylphenidate extended-release capsules administered once daily to children with attention-deficit/hyperactivity disorder.

All three doses of d-MPH XR were significantly more effective than placebo in improving ADHD symptoms as confirmed by the teacher, parent and clinician and demonstrated a consistent safety profile.

Efficacy and safety of dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder.

Once-daily d-MPH-ER was more effective than placebo in the treatment of ADHD in children and adolescents.

A Randomized, Double-Blind, Crossover Study of Once-Daily Dexmethylphenidate in Children with Attention-Deficit Hyperactivity Disorder

Compared with placebo, once-daily dexmethylphenidate ER 20 mg provided rapid and significant improvement at 0.5 hours post-dose in attention, deportment and academic performance, which was sustained for 8 hoursPost-dose.

Effect of Switching Drug Formulations from Immediate-Release to Extended-Release OROS Methylphenidate

The switch from IR methylphenidate to OROSmethylphenidate was associated with a statistically significant improvement in all items of the SMAQ questionnaire and was more effective than IR methyl phenidate in reducing symptoms of ADHD.

Efficacy and safety of extended-release dexmethylphenidate compared with d,l-methylphenidate and placebo in the treatment of children with attention-deficit/hyperactivity disorder: a 12-hour laboratory classroom study.

d-MPH-ER and d,l-MPh-ER improved ADHD symptoms and were well tolerated and all active treatments provided a significant benefit over placebo at most time points to 12 hours post-dosing.

Efficacy and duration of effect of extended-release dexmethylphenidate versus placebo in schoolchildren with attention-deficit/hyperactivity disorder.

D-MPH-ER is safe and effective and improves classroom attention, deportment, and performance in children with ADHD and maintained significant superiority over placebo from hours 1 through 12.
...